JOP20190280A1 - مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية - Google Patents

مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Info

Publication number
JOP20190280A1
JOP20190280A1 JOP/2019/0280A JOP20190280A JOP20190280A1 JO P20190280 A1 JOP20190280 A1 JO P20190280A1 JO P20190280 A JOP20190280 A JO P20190280A JO P20190280 A1 JOP20190280 A1 JO P20190280A1
Authority
JO
Jordan
Prior art keywords
treating
patient
treating cholangiocarcinoma
fgfr2
fgfr2 inhibitors
Prior art date
Application number
JOP/2019/0280A
Other languages
English (en)
Inventor
Jacqueline Cirillo Bussolari
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20190280A1 publication Critical patent/JOP20190280A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

تم الكشف فيما يلي عن طرق علاج سرطان الأوعية الصفراوية في مريض تتضمن: تقييم عينة بيولوجية من المريض من حيث وجود واحد أو أكثر من متطفرات FGFR شاملة على الأقل FGFR2 SNP C383R؛ وعلاج المريض بمثبط FGFR في حال تواجد واحد أو أكثر من متطفرات FGFR تشمل على الأقل FGFR2 SNP C383R في العينة.
JOP/2019/0280A 2017-06-02 2017-06-16 مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية JOP20190280A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17174295 2017-06-02
EP18171315 2018-05-08

Publications (1)

Publication Number Publication Date
JOP20190280A1 true JOP20190280A1 (ar) 2019-12-02

Family

ID=62555054

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0280A JOP20190280A1 (ar) 2017-06-02 2017-06-16 مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Country Status (16)

Country Link
US (2) US11707463B2 (ar)
EP (1) EP3634414A1 (ar)
JP (2) JP2020521794A (ar)
KR (1) KR20200010505A (ar)
CN (1) CN111050769A (ar)
AU (1) AU2018278271B2 (ar)
BR (1) BR112019025056A2 (ar)
CA (1) CA3064317A1 (ar)
IL (1) IL271058A (ar)
JO (1) JOP20190280A1 (ar)
MA (1) MA49248A (ar)
MX (1) MX2019014366A (ar)
MY (1) MY204203A (ar)
PH (1) PH12019502710A1 (ar)
UA (1) UA126478C2 (ar)
WO (1) WO2018220206A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39784B1 (fr) 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
JO3695B1 (ar) 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
CN113423402A (zh) * 2019-02-12 2021-09-21 詹森药业有限公司 癌症治疗
CN113645974A (zh) * 2019-03-29 2021-11-12 詹森药业有限公司 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
WO2020243273A2 (en) * 2019-05-28 2020-12-03 Qed Therapeutics, Inc. Methods of treating cholangiocarcinoma
WO2021023178A1 (zh) * 2019-08-05 2021-02-11 江苏恒瑞医药股份有限公司 一种吡咯并六元杂环化合物在制备治疗fgfr2基因变异的肿瘤的药物中的用途
JP2023512482A (ja) * 2020-01-17 2023-03-27 ベータ・ファーマ・インコーポレイテッド Ｆｇｆｒキナーゼ阻害剤としてのピリダジンおよび１，２，４－トリアジン誘導体
CN111596058A (zh) * 2020-05-18 2020-08-28 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
KR20250117064A (ko) 2024-01-26 2025-08-04 충북대학교 산학협력단 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
AU2008230880B2 (en) * 2007-03-23 2014-04-24 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
CR20170104A (es) 2014-09-26 2017-05-31 Janssen Pharmaceutica Nv Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
EP3365335B1 (en) 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
JP2023113650A (ja) 2023-08-16
CA3064317A1 (en) 2018-12-06
EP3634414A1 (en) 2020-04-15
JP2020521794A (ja) 2020-07-27
IL271058A (en) 2020-01-30
AU2018278271B2 (en) 2024-07-04
MX2019014366A (es) 2020-07-27
AU2018278271A1 (en) 2019-12-05
US20240016801A1 (en) 2024-01-18
MY204203A (en) 2024-08-15
PH12019502710A1 (en) 2020-06-08
BR112019025056A2 (pt) 2020-06-16
US20200138809A1 (en) 2020-05-07
MA49248A (fr) 2020-04-15
US12350266B2 (en) 2025-07-08
US11707463B2 (en) 2023-07-25
WO2018220206A1 (en) 2018-12-06
KR20200010505A (ko) 2020-01-30
UA126478C2 (uk) 2022-10-12
CN111050769A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
PH12019502710A1 (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
CY1125190T1 (el) Χρηση ομαδων γονιδιων fgfr μεταλλαγματων στην εξακριβωση του εαν καρκινοπαθεις θα αποκρινονται σε αγωγη me fgfr αναστολεα
CR20230500A (es) Métodos para inhibir ras
CL2017002123A1 (es) Heterociclos biciclicos como inhibidores de fgnr
CL2018001110A1 (es) Mutaciones de punto en cáncer resistente a inhibidor de trk y métodos relacionados con el mismo
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
PH12017501967A1 (en) Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201992026A1 (ru) Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
MX2018008166A (es) Sistemas y metodos para confirmar la activacion de indicadores biologicos.
AR100766A1 (es) Sistema de expresión génica
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EP4407047A3 (en) Molecular detection of enterovirus and parechovirus
EA201992849A1 (ru) Ингибиторы fgfr2 для лечения холангиокарциномы
EA202190826A1 (ru) Лечение холангиокарциномы
UA95580U (uk) Спосіб прогнозування зрощення перелому
UA95591U (uk) Спосіб прогнозування зрощення перелому
RU2015110486A (ru) Способ оценки результатов воздействия микроорганизмов на пролиферацию клеток в макроорганизме
UA95656U (uk) Спосіб прогнозування зрощення перелому
UA94790U (uk) Спосіб прогнозування зрощення перелому
BR112017010902A2 (pt) método para identificar a presença ou ausência de um ácido nucleico alvo em uma amostra biológica.
UA95639U (uk) Спосіб прогнозування зрощення перелому
UA98477U (uk) Спосіб визначення маркера системного запалення шляхом оцінки макрофагальної реакції жирової тканини